SPARTA

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

Retrieved on: 
Tuesday, October 31, 2023
APLM, Colon, NSCLC, GBM, C-2, Hepatocyte growth factor, Conference, Glioblastoma, SPARTA, WCLC, Washington University School of Medicine, Cancer, HGF, Pancreatic cancer, Brain, Lung cancer, Safety, IST, Patient, MET, EGFR, Pharmaceutical industry

The second new cohort, labeled F, will evaluate vebreltinib monotherapy in histology-agnostic solid tumors with wild type MET gene that have high expression of c-MET and hepatocyte growth factor (HGF).

Key Points: 
  • The second new cohort, labeled F, will evaluate vebreltinib monotherapy in histology-agnostic solid tumors with wild type MET gene that have high expression of c-MET and hepatocyte growth factor (HGF).
  • Dr. Bindiya Patel and Dr. Siddhartha Devarakonda presented this study during a poster session on September 11, 2023, at the World Conference on Lung Cancer (WCLC) in Singapore.
  • A link to the WCLC poster is available under the Investors tab of the Apollomics website at https://www.apollomicsinc.com .
  • It works by inhibiting the aberrant activation of the HGF/c-MET axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies such as osimertinib.

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

Retrieved on: 
Thursday, October 26, 2023
APLM, National Medical Products Administration, GBM, Temozolomide, NMPA, ESMO, SPARTA, Radiation, Cancer, Partial-response maximum-likelihood, New Drug Application, NDA, European Society for Medical Oncology, Patient, MET, Communication, Aviston, Illinois, Pharmaceutical industry

The patient with GBM with PTPRZ-MET fusion who had previously received radiotherapy and temozolomide, was reported to have an impressive Partial Response (PR) after 8 weeks of treatment with vebreltinib monotherapy during participation in the SPARTA study ( NCT03175224 ) .

Key Points: 
  • The patient with GBM with PTPRZ-MET fusion who had previously received radiotherapy and temozolomide, was reported to have an impressive Partial Response (PR) after 8 weeks of treatment with vebreltinib monotherapy during participation in the SPARTA study ( NCT03175224 ) .
  • “PTPRZ-MET fusions are known to cause aggressive forms of GBM and are associated with poor prognosis.
  • We are pleased to achieve positive clinical results in patients with this deadly disease, further demonstrating the potential of vebreltinib as a new treatment for patients with cancers driven by MET alterations,” said Guo-Liang Yu, Ph.D., co-founder, Chairman and Chief Executive Officer of Apollomics.
  • GBM with MET fusion is an indication pursued by Apollomics and its China partner, Avistone Biotechnology.

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

Retrieved on: 
Monday, October 16, 2023
Cohort, Medicine, Abstract, NSCLC, GBM, APLM, Hospital, IDH, ESMO, SPARTA, European Society for Medical Oncology, Southern Medical University, Yang, Patient, Poster, Pharmaceutical industry, Nursing

FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that two abstracts detailing vebreltinib data were made available as part of the European Society of Medical Oncology Congress (ESMO) 2023 being held in Madrid, Spain from October 20-24, 2023.

Key Points: 
  • FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that two abstracts detailing vebreltinib data were made available as part of the European Society of Medical Oncology Congress (ESMO) 2023 being held in Madrid, Spain from October 20-24, 2023.
  • The poster will include data from patients with METex14 mutation (Cohort 1) from the Phase 2, open-label, multicenter and multi-cohort study.
  • "Vebreltinib continues to yield compelling data, reinforcing its potential as a vital treatment option for patients with challenging-to-treat cancers driven by c-MET alterations,” said Guo-Liang Yu, Ph.D., co-founder, Chairman and Chief Executive Officer of Apollomics.
  • Presentation materials will be available on the Apollomics website following the presentations at ESMO: https://ir.apollomicsinc.com/news-events/presentations .

Sparta Science Awarded U.S. Air Force Small Business Innovation Research Phase I Contract

Retrieved on: 
Thursday, December 15, 2022
Structure of the United States Space Force, United, Atmosphere, USAF, GRT, Qatar General Broadcasting and Television Corporation, AFWERX, Science, United States Air Force Medical Service, Air force, U.S. Department of Defense Strategy for Operating in Cyberspace, USSF, SBIR, Guardian, Research, Obesity, Government, Space force, Artificial intelligence, SPARTA, Workforce, Hypertension, Movement, Health, Performance medicine, Machine learning, Acquisition, Organization, Medical device, Management

MENLO PARK, Calif., Dec. 15, 2022 /PRNewswire/ -- Sparta Science, the developer of a scalable, machine learning-based movement health platform, was recently awarded an AFWERX Small Business Innovation Research (SBIR) Phase I contract by the United States Air Force to apply artificial intelligence (AI) and machine learning (ML) embedded in cloud and mobile apps to extend the reach and productivity of Space Force's Guardian Resiliency Teams (GRT) in their mission to optimize individual Guardians' performance. This award is significant as it aims to improve Guardians' coping mechanisms to operational stressors through Lifestyle & Performance Medicine across the United States Space Force.

Key Points: 
  • Under this award, Sparta Science will explore research and development partnerships with GRTs across the Space Force as well as transition and acquisition strategies with program offices such as Air Force Medical Service.
  • ABOUT SPARTA SCIENCE: Sparta Science was founded with the vision that everybody should be able to move freely, without physical limitations, for as long as possible.
  • ABOUT AFRL: The air force research laboratory (afrl) is the primary scientific research and development center for the department of the air force.
  • ABOUT AFWERX: Afwerx, a program office at the air force research laboratory (afrl), connects innovators across government, industry and academia.